Comprehensive and relevant chemistry and bioactivity related content reduces time taken for research and supports rapid user adoption
Karo Bio, a Swedish pharmaceutical developer, has started to use Elsevier’s Reaxys and Reaxys Medicinal Chemistry workflow solutions. The firm will use them to support its chemists in their research and development objectives, ensuring that they have quick and easy access to the most up to date chemistry information.
‘Comprehensive content is critical to our chemists and the Reaxys solutions give them more relevant results in a single search than other solutions could offer,’ said Maria Sjöberg, Chief Scientific Officer at Karo Bio.
‘Not only do our chemists have access to more data, including biological as well as chemical information, but the content is more applicable to their research. We expect the availability of the Reaxys Medicinal Chemistry information alone will reduce research and development time by approximately 20%.’
Reaxys encompasses the content of more than 16,000 periodicals while Reaxys Medicinal Chemistry offers access to data from a vast repository of peer-reviewed journal articles and patents.
‘Researchers in life sciences face an ever growing challenge in making confident and successful decisions in a changing landscape,’ said Juergen Swienty-Busch, Head of Product Management for Reaxys.
‘Karo Bio has a unique knowledge of nuclear receptors as target proteins for the development of novel pharmaceuticals. We are excited that the Reaxys solutions will play a part in increasing the speed at which these projects to discover innovative compounds come to fruition.’
Reaxys and Reaxys Medicinal Chemistry are part of Elsevier Life Science Solutions, a suite of interoperable tools, which span the discovery and development workflow.
Reaxys combines reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning. Researchers can get the information they need in a single overview.